14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
ASTH vs FOFO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Astrana Health Inc. (ASTH) is the stronger overall head-to-head candidate over Hang Feng Technology Innovation Co., Ltd. (FOFO) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ASTH carries a Unified Composite Score of 48.8/100 (HOLD) at $28.90 (8.3x Forward P/E, 2.6% operating margin), whereas FOFO carries 43.0/100 (HOLD) at $1.50 (N/M Forward P/E, -823.6% operating margin).
Technical & Structure Timing Caution: ASTH is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.1); meanwhile FOFO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ASTH vs FOFO. Trailing 12-month operating profitability (ASTH 2.6% vs FOFO -823.6%) and valuation multiples (ASTH 8.3x vs FOFO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Consulting Services value chain with $12.8M market capitalization and -823.6% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ASTH vs FOFO Key Questions & Quantitative Answers
As of Nov 20, 2026, Astrana Health Inc. (ASTH) is the stronger overall head-to-head candidate over Hang Feng Technology Innovation Co., Ltd. (FOFO) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ASTH carries a Unified Composite Score of 48.8/100 (HOLD) at $28.90 (8.3x Forward P/E, 2.6% operating margin), whereas FOFO carries 43.0/100 (HOLD) at $1.50 (N/M Forward P/E, -823.6% operating margin). Technical & Structure Timing Caution: ASTH is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.1); meanwhile FOFO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ASTH leads the Growth & Scale pillar: ASTH posts +7.1% YoY revenue growth and N/A YoY earnings growth on $3.91B TTM revenue (11.0% gross margin, 2.6% operating margin), compared with FOFO at -72.7% YoY revenue growth and +0.0% YoY earnings growth on $1.4M TTM revenue (7.0% gross margin, -823.6% operating margin). On trailing 12-month operating scale, ASTH generates $3.91B in USD-normalized revenue versus $1.4M for FOFO. In operating R&D and SG&A reinvestment, ASTH deploys 8.4% of Rev ($329M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for FOFO.
ASTH screens cheaper on headline valuation multiples. ASTH trades at 8.3x Forward P/E, 26.6x Trailing P/E, N/M PEG, and 0.5x EV/Revenue (2.5% FCF margin), whereas FOFO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.4x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ASTH (9.8% ROE) versus FOFO (-169.2% ROE) capital efficiency.
In options market volatility and institutional positioning, ASTH carries 52.0% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.40β · 60% Vol realized risk). By comparison, FOFO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.45β · 65% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.